Non-Hodgkin Lymphoma (NHL) Market Outlook

Thelansis’s “Non-Hodgkin Lymphoma (NHL) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Non-Hodgkin Lymphoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Non-Hodgkin Lymphoma (NHL) Overview

Non-Hodgkin Lymphoma (NHL) is a highly heterogeneous group of hematologic malignancies originating from the clonal proliferation of neoplastic B cells, T cells, or natural killer (NK) cells at varying stages of differentiation. Driven by distinct somatic alterations such as the t(14;18) translocation upregulating BCL2 in follicular lymphoma or MYC rearrangements in Burkitt lymphoma, NHL is broadly categorized clinically into indolent (slow-growing) and aggressive variants. Diffuse large B-cell lymphoma (DLBCL) represents the most common aggressive subtype, whereas follicular lymphoma is the most prevalent indolent form. Patients typically present with painless, persistent lymphadenopathy, hepatosplenomegaly, and systemic B symptoms including fever, night sweats, and unexplained weight loss. Diagnosis mandates an excisional lymph node biopsy for detailed morphology and immunophenotyping via flow cytometry or immunohistochemistry, supplemented by PET-CT for Lugano system clinical staging. In 2026, frontline therapy for aggressive B-cell NHL universally pairs standard immuno-chemotherapy (R-CHOP) with targeted polatuzumab vedotin, whereas refractory or relapsed disease is heavily managed using anti-CD19 chimeric antigen receptor (CAR) T-cell therapies or bispecific T-cell engagers (BiTEs) like epcoritamab. Prognosis varies extensively by exact histopathological subtype, molecular risk profiles, and patient age, necessitating highly specialized, personalized hematologic tracking to balance curative intent with long-term toxic survivorship monitoring.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025–2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)